CD16(+) macrophages: An emerging biomarker for combined CTLA-4 and PD-1 blockade Editorial
| Authors: | Smithy, J. W.; Luke, J. J. |
| Title: | CD16(+) macrophages: An emerging biomarker for combined CTLA-4 and PD-1 blockade |
| Abstract: | In a retrospective analysis of patients with unresectable melanoma, higher pretreatment tissue densities of CD16+ macrophages were associated with clinical benefit from combined CTLA-4 and PD-1 blockade. With further validation, this biomarker could serve as a tool in selecting between immune checkpoint inhibitor regimens. See related article by Lee et al., p. 2513. ©2023 American Association for Cancer Research. |
| Keywords: | retrospective studies; biomarkers; biological marker; melanoma; pathology; retrospective study; cytotoxic t lymphocyte antigen 4; macrophage; macrophages; immune checkpoint inhibitor; ctla-4 antigen; humans; human; immune checkpoint inhibitors |
| Journal Title: | Clinical Cancer Research |
| Volume: | 29 |
| Issue: | 13 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2023-07-01 |
| Start Page: | 2345 |
| End Page: | 2347 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-23-0490 |
| PUBMED: | 37097465 |
| PROVIDER: | scopus |
| PMCID: | PMC10330271 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus |
